Nearly 200 Quantitative Immunoassays for Discovery and Validation of New Biomarker Panels
AUSTIN, Texas, June 17 /PRNewswire/ -- Rules-Based Medicine, Incorporated (RBM), the world's leading multiplexed biomarker testing laboratory, today announced the availability of the most comprehensive collection of quantitative immunoassays for use in advancing safety, efficacy and efficiency in drug and diagnostic development. The new service, DiscoveryMAP(TM) v 1.0, offers customers dynamic coverage of most physiologically relevant pathways, providing biological information and leads for further study. This unique and comprehensive offering increases the odds of identifying new protein biomarker patterns in almost any drug development or diagnostic discovery project.
"Despite the known benefits of biomarkers in drug development, many biomarker discovery efforts fail to contribute because the patterns do not reproduce on a clinically validated platform. The RBM approach is to discover new biomarker patterns on the same platform that will be used in clinical trials," said Craig Benson, RBM chief executive officer. "DiscoveryMAP(TM) was designed in collaboration with our pharmaceutical and biotech customers and includes biomarkers known to be important in the major disease indications for drug development. Once a pattern is discovered, we can seamlessly convert those biomarkers into a new custom panel for high-throughput sample processing."
DiscoveryMAP(TM) v 1.0 utilizes RBM's proprietary multi-analyte profiling (MAP) platform to quantify key blood-based biomarkers representing dozens of important biological pathways.
DiscoveryMAP(TM) provides customers with the most robust, quantitative data compared to any available proteomic service or platform technology. All samples are processed in RBM's CLIA-certified lab using proprietary reagents and software to give the most accurate and reproducible p
|SOURCE Rules-Based Medicine, Incorporated|
Copyright©2009 PR Newswire.
All rights reserved